Engineered Cannabinoid Biomarkers for Real-Time CB1/CB2 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for testing cannabinoid drugs using animal models are costly, time-consuming, and provide limited accuracy, with indirect assays failing to accurately predict human response and involving significant animal use.
Innovation Solution
Development of engineered biomarkers (AxCBM1 and AxCBM2) that bind to cannabinoid receptors, enabling real-time, direct observation and quantification of receptor activity in human cells, allowing for faster and more accurate testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal models are used for testing cannabinoid drugs, then safety and efficacy can be assessed, but the testing process becomes costly, time-consuming, and provides limited accuracy
Solution Approach 1:
The patent creates a simplified in vitro copy of the human cannabinoid receptor system using HEK293 cells engineered to express human CB1 and CB2 receptors. This cell-based model replicates key aspects of human receptor biology without requiring complex animal models, thereby reducing testing time while maintaining predictive accuracy for human response
Solution Approach 2:
The patent replaces the mechanical/physiological complexity of whole animal models with a controlled in vitro cell-based system. By substituting animal subjects with engineered human cells and using automated imaging and analysis systems, the methodology eliminates interspecies variability and reduces testing time while improving reliability
2Reliability
If animal models are used for testing cannabinoid drugs, then safety and efficacy can be assessed, but the cost and resource requirements increase significantly
Solution Approach 1:
The patent creates a simplified in vitro copy of the human cannabinoid receptor system using HEK293 cells engineered to express human CB1 and CB2 receptors. This cell-based model replicates key aspects of human receptor biology without requiring complex animal models, thereby reducing testing time while maintaining predictive accuracy for human response
Solution Approach 2:
The patent employs disposable in vitro cell cultures instead of expensive, long-lived animal models. The engineered HEK293 cells can be rapidly cultured, tested, and discarded, eliminating the high costs associated with animal housing, care, and ethical compliance while maintaining scientific validity
3Adaptability or versatility
If indirect downstream assays are used to detect receptor activity, then general GPCR activity can be measured, but specific cannabinoid receptor dynamics and pathways cannot be distinguished
Solution Approach 1:
The patent applies local quality by engineering specific HEK293 cell lines to express only human CB1 or CB2 receptors, creating localized systems that detect only cannabinoid-specific signaling pathways. This specificity is further enhanced by using cannabinoid-selective ligands that bind only to their target receptors, eliminating cross-talk with other GPCR pathways
Solution Approach 2:
The patent segments the detection system into separate specialized cell lines for CB1 and CB2 receptors, each optimized for detecting specific cannabinoid ligands. This segmentation allows independent optimization of detection parameters for each receptor type and eliminates signal interference that would occur in mixed-receptor systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biomarkers provide 99% accurate, real-time observation of receptor response, reducing testing time to seconds and costs, while eliminating the need for animal models, thus enhancing drug development efficiency.
Implementation Method 1
designed to be capable of binding with fluorescent molecules that 'tag' two Cannabis receptors (CBI and CB2)
Data Source
AI summary
Methods and applications to label, detect and engineer native or recombinant CB1 and CB2 receptors for cannabinoid chemicals are provided. Also disclosed are uses to detect the dynamics and real time pharmacokinetics of cannabinoid receptors, and purification of cannabinoid receptors in vivo (humans, animals etc.) and in vitro (in the cells).